bioMérieux S.A. (BMXXY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

bioMérieux S.A. (BMXXY) Healthcare & Pipeline Overview

bioMérieux S.A. is a global in vitro diagnostics company specializing in infectious disease and industrial microbiological testing. With a focus on clinical and industrial applications, the company serves a diverse range of customers, including hospitals, laboratories, and the food, pharmaceutical, and cosmetic industries, positioning itself in a growing healthcare market.

What Is the Investment Thesis for BMXXY?

bioMérieux S.A. presents a compelling investment case based on its established market position, consistent financial performance, and growth opportunities in the in vitro diagnostics sector. The company's diverse product portfolio and global presence provide a stable revenue base, while its focus on innovation and strategic acquisitions drive future growth. With a P/E ratio of 20.8 and a profit margin of 9.8%, bioMérieux demonstrates financial stability. Upcoming catalysts include expansion into emerging markets and development of new diagnostic solutions. Potential risks include regulatory changes and increased competition. The company's dividend yield of 0.95% offers a modest return while investors await further growth.

Based on FMP financials and quantitative analysis

BMXXY Key Highlights

• Market capitalization of $9.71B, reflecting its significant presence in the in vitro diagnostics market.
• P/E ratio of 20.8, indicating investor confidence in the company's earnings potential.
• Profit margin of 9.8%, demonstrating efficient operations and profitability.
• Gross margin of 53.1%, showcasing the company's ability to maintain pricing power and manage costs effectively.
• Dividend yield of 0.95%, providing a steady income stream for investors.

Who Are BMXXY's Competitors?

BMXXY is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BMXXY's Key Strengths?

• Global presence and established distribution network.
• Diverse product portfolio covering a wide range of diagnostic applications.
• Strong focus on innovation and research and development.
• Reputation for high-quality products and services.

What Are BMXXY's Weaknesses?

• Exposure to currency fluctuations due to international operations.
• Dependence on regulatory approvals for new products.
• Competition from larger and more diversified companies.
• Potential for product recalls or liability claims.

What Could Drive BMXXY Stock Higher?

• Expansion into emerging markets, particularly in Asia Pacific and Latin America, is expected to drive revenue growth.
• Launch of new diagnostic solutions for emerging infectious diseases and chronic conditions in the next 1-2 years.
• Strategic acquisitions and partnerships to expand product portfolio and geographic reach.
• Increasing demand for microbiological testing in the food, pharmaceutical, and cosmetic industries.
• Integration of digital technologies, such as artificial intelligence and data analytics, into diagnostic solutions.

What Are the Key Risks for BMXXY?

• Increased competition from existing and new players in the in vitro diagnostics market.
• Changes in regulatory requirements and healthcare policies could impact the company's operations and profitability.
• Economic downturns could reduce healthcare spending and demand for diagnostic solutions.
• Technological disruptions could render existing products obsolete.
• Exposure to currency fluctuations due to international operations.

What Are the Growth Opportunities for BMXXY?

• Expansion in Emerging Markets: bioMérieux has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare infrastructure is developing and demand for diagnostic solutions is increasing. These regions offer high growth potential due to their large populations and increasing healthcare spending. By establishing strategic partnerships and tailoring its product offerings to local needs, bioMérieux can capture a significant share of these rapidly growing markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Development of New Diagnostic Solutions: Investing in research and development to create innovative diagnostic solutions for emerging infectious diseases and chronic conditions represents a significant growth opportunity. By leveraging its expertise in molecular diagnostics and microbiology, bioMérieux can develop tests that offer faster, more accurate results, improving patient outcomes and driving revenue growth. Focus areas include antimicrobial resistance, respiratory infections, and personalized medicine. Successful product launches in these areas could drive revenue growth over the next 2-4 years.
• Strategic Acquisitions and Partnerships: bioMérieux can pursue strategic acquisitions and partnerships to expand its product portfolio, geographic reach, and technological capabilities. By acquiring companies with complementary technologies or market access, bioMérieux can accelerate its growth and strengthen its competitive position. Potential targets include companies specializing in point-of-care testing, digital diagnostics, and data analytics. Strategic partnerships can also provide access to new markets and technologies, driving innovation and revenue growth over the next 2-5 years.
• Focus on Industrial Microbiology: bioMérieux can capitalize on the growing demand for microbiological testing in the food, pharmaceutical, and cosmetic industries. As regulatory requirements become more stringent and consumer awareness of food safety increases, companies are investing more in quality control and testing. bioMérieux can leverage its expertise in industrial microbiology to provide comprehensive testing solutions that help companies ensure the safety and quality of their products. This focus can lead to increased revenue and market share in the industrial sector over the next 1-3 years.
• Leveraging Digital Technologies: Integrating digital technologies, such as artificial intelligence and data analytics, into its diagnostic solutions can enhance their accuracy, efficiency, and accessibility. By developing AI-powered diagnostic tools that can analyze large datasets and provide personalized insights, bioMérieux can improve patient outcomes and reduce healthcare costs. Additionally, digital platforms can facilitate remote monitoring and data sharing, improving access to diagnostic services in underserved areas. This integration can drive innovation and create new revenue streams over the next 3-5 years.

What Opportunities Does BMXXY Have?

• Expansion into emerging markets with growing healthcare spending.
• Development of new diagnostic solutions for emerging infectious diseases.
• Strategic acquisitions and partnerships to expand product portfolio and geographic reach.
• Increasing demand for microbiological testing in the food, pharmaceutical, and cosmetic industries.

What Threats Does BMXXY Face?

• Increased competition from existing and new players.
• Changes in regulatory requirements and healthcare policies.
• Economic downturns that could reduce healthcare spending.
• Technological disruptions that could render existing products obsolete.

What Are BMXXY's Competitive Advantages?

• Established brand reputation and long-standing customer relationships.
• Extensive portfolio of diagnostic solutions covering a wide range of diseases and applications.
• Strong focus on innovation and research and development.
• Global presence and distribution network.
• High switching costs for customers due to regulatory requirements and validation processes.

What Does BMXXY Do?

bioMérieux S.A., founded in 1963 and headquartered in Marcy l'Etoile, France, is a global leader in the field of in vitro diagnostics. Originally known as B-D Mérieux, the company develops, manufactures, and markets diagnostic solutions used to detect and analyze infectious diseases, cardiovascular pathologies, and cancers. Its products and services cater to clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company's offerings include diagnostic systems and reagents used on biological samples, as well as microbiological testing solutions for industrial applications, primarily in the food, pharmaceutical, cosmetics, and veterinary sectors. bioMérieux operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. As a subsidiary of Institut Mérieux SA, bioMérieux leverages its parent company's resources and expertise to drive innovation and expand its global footprint. The company's commitment to improving public health through diagnostic solutions has solidified its position as a key player in the healthcare industry.

What Products and Services Does BMXXY Offer?

• Develops and produces in vitro diagnostic solutions.
• Offers systems for diagnosing infectious diseases.
• Provides solutions for diagnosing cardiovascular pathologies.
• Offers solutions for diagnosing various cancers.
• Provides microbiological testing for food, pharmaceutical, cosmetics, and veterinary sectors.
• Serves clinical and hospital laboratories.
• Caters to physicians and blood banks.
• Supports industrial control laboratories.

How Does BMXXY Make Money?

• Develops and manufactures in vitro diagnostic systems and reagents.
• Sells diagnostic solutions to clinical and industrial customers.
• Provides service and support for its installed base of diagnostic systems.
• Generates revenue through reagent sales, instrument placements, and service contracts.

What Industry Does BMXXY Operate In?

bioMérieux S.A. operates in the in vitro diagnostics market, a sector driven by increasing healthcare expenditure, an aging global population, and the rising prevalence of infectious diseases. The market is characterized by technological advancements, such as molecular diagnostics and point-of-care testing. bioMérieux competes with companies like ALPMY, GIKLY, GNMSF, ORINY, and SAUHF, focusing on innovation and strategic partnerships to maintain its competitive edge. The global in vitro diagnostics market is projected to continue growing, presenting significant opportunities for bioMérieux.

Who Are BMXXY's Key Customers?

• Clinical and hospital laboratories
• Physicians
• Blood banks
• Industrial control laboratories (food, pharmaceutical, cosmetics, veterinary)

Company Profile

bioMérieux S.A. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Marcy l'Étoile, FR. The company is led by CEO Pierre Boulud. BMXXY has traded publicly since 2023.

bioMérieux S.A. Financial Trajectory

bioMérieux S.A. (BMXXY) reported $2.01B in revenue for Q4 2025, a decline of 1.6% compared to the prior quarter. The company recorded net income of $234.6M, with diluted EPS of $0.20. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, BMXXY averaged $0.17 in diluted EPS.

How bioMérieux S.A. Is Valued

bioMérieux S.A. carries a market capitalization of $9.71B, placing it in the mid-cap category. Relative to its peer group, BMXXY's quantitative score of 46/100 is roughly in line with the peer average of 55/100.

ROE 10%Key Financial Metrics

Return on equity for bioMérieux S.A. stands at 9.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. BMXXY trades at a trailing price-to-earnings ratio of 20.79, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 8/9Financial Health

bioMérieux S.A.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.98 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project bioMérieux S.A. revenue of about $4.11B for fiscal 2026, with EPS near $0.00. The estimate reflects 13 contributing analysts.

BMXXY Financials

BMXXY Latest News

BMXXY Analyst Consensus

BMXXY MoonshotScore

Common Questions About BMXXY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources